Author/Authors :
Bakherad, Hamid Department of Pharmaceutical Biotechnology - Isfahan University of Medical Sciences, Isfahan, I.R. Iran , Setayesh, Neda Department of Pharmaceutical Biotechnology - Faculty of Pharmacy - Tehran University of Medical Sciences, Tehran, I.R. Iran , Mousavi Gargari, Latif Department of Biology - Faculty of Basic Science - Shahed University, Tehran, I.R. Iran , Ebrahimizadeh, Walead Department of Surgery - Division of Urology - McGill University and the Research Institute of the McGill University Health Centre (RI MUHC), Montreal, Quebec, Canada , Mavandadnejad, Faranak Department of Pharmaceutical Biotechnology - Tehran University of Medical Sciences, Tehran, I.R. Iran , Faghfuri, Elnaz Digestive Disease Research Center - Ardabil University of Medical Sciences, Ardabil, I.R. Iran , Ebrahimi, Soheila Department of Pharmaceutical Biotechnology - Faculty of Pharmacy - Tehran University of Medical Sciences, Tehran, I.R. Iran , Heiat, Mohammad Baqiyatallah Research Center for Gastroenterology and Liver Diseases - Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran , Shahpari, Mona Department of Pharmaceutical Biotechnology - Faculty of Pharmacy - Tehran University of Medical Sciences, Tehran, I.R. Iran , Sepehrizadeh, Zargham Department of Pharmaceutical Biotechnology - Faculty of Pharmacy - Tehran University of Medical Sciences, Tehran, I.R. Iran
Abstract :
Background and purpose: Granulocyte colony-stimulating factor (G-CSF) is routinely used in combination with chemotherapy to battle neutropenia. However, studies suggest that this chemokine may increase the risk of metastasis and malignancy in many cancers. To counteract the adverse effects of G-CSF in cancer, antibodies have been used to block its action. However, antibodies are large and complex molecules which makes their production expensive. Thus in this study, we aim to construct different structure variants of the G-CSF receptor containing different domains and select the best variant that prevents the adverse actions of this chemokine. These novel structures are smaller than antibodies and easier to produce.
Experimental approach: Different domains of the G-CSF receptor were designed and cloned into the pET28a expression vector. These recombinant receptor subunits were then expressed in Escherichia coli and purified using standard affinity chromatography techniques. Interaction of recombinant receptor subunits with G-CSF was assessed using enzyme-linked immunosorbent assay and NFS60 cells.
Findings / Results: Two recombinant receptor subunits containing D1 + D2 + D3 domains and D2 domain showed the strongest inhibitory activity to G-CSF.
Conclusion and implications: These novel recombinant receptor variants could be candidates for further studies in the development of novel therapeutics.
